NP_001269030.1
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
yorkie homolog isoform 9
NCBI Official Synonym Full Names
Yes-associated protein 1
NCBI Protein Information
yorkie homolog; yes-associated protein 2; 65 kDa Yes-associated protein
UniProt Protein Name
Yorkie homolog
UniProt Synonym Protein Names
65 kDa Yes-associated protein
UniProt Synonym Gene Names
UniProt Entry Name
YAP1_HUMAN
NCBI Summary for YAP1
This gene encodes a downstream nuclear effector of the Hippo signaling pathway which is involved in development, growth, repair, and homeostasis. This gene is known to play a role in the development and progression of multiple cancers as a transcriptional regulator of this signaling pathway and may function as a potential target for cancer treatment. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Aug 2013]
UniProt Comments for YAP1
Function: Transcriptional regulator which can act both as a coactivator and a corepressor and is the critical downstream regulatory target in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Plays a key role to control cell proliferation in response to cell contact. Phosphorylation of YAP1 by LATS1/2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. The presence of TEAD transcription factors are required for it to stimulate gene expression, cell growth, anchorage-independent growth, and epithelial mesenchymal transition (EMT) induction. Isoform 2 and isoform 3 can activate the C-terminal fragment (CTF) of ERBB4 (isoform 3). Ref.2 Ref.11 Ref.13 Ref.14 Ref.15 Ref.19
Subunit structure: Binds to the SH3 domain of the YES kinase. Binds to WBP1 and WBP2. Binds, in vitro, through the WW1 domain, to neural isoforms of ENAH that contain the PPSY motif
By similarity. The phosphorylated form interacts with YWHAB. Interacts (via WW domains) with LATS1 (via PPxY motif 2). Interacts with LATS2. Isoform 2 and isoform 3 interact (via WW domain 1) with isoform 3 of ERBB4 (via PPxY motif 2). Interacts with TEAD1, TEAD2, TEAD3 and TEAD4. Interacts with TP73. Interacts with RUNX1. Interacts with HCK. Interacts (via WW domains) with PTPN14 (via PPxY motif 2); this interaction leads to the cytoplasmic sequestration of YAP1 and inhibits its transcriptional coactivator activity. Ref.2 Ref.7 Ref.10 Ref.11 Ref.13 Ref.14 Ref.15 Ref.21 Ref.22 Ref.26
Subcellular location: Cytoplasm. Nucleus. Note: Both phosphorylation and cell density can regulate its subcellular localization. Phosphorylation sequesters it in the cytoplasm by inhibiting its translocation into the nucleus. At low density, predominantly nuclear and is translocated to the cytoplasm at high density. PTPN14 induces translocation from the nucleus to the cytoplasm. Ref.11 Ref.14 Ref.15 Ref.20 Ref.26
Tissue specificity: Increased expression seen in some liver and prostate cancers. Isoforms lacking the transactivation domain found in striatal neurons of patients with Huntington disease (at protein level). Ref.1 Ref.9 Ref.11
Post-translational modification: Phosphorylated by LATS1 and LATS2; leading to cytoplasmic translocation and inactivation. Phosphorylated by ABL1; leading to YAP1 stabilization, enhanced interaction with TP73 and recruitment onto proapoptotic genes; in response to DNA damage. Phosphorylation at Ser-400 and Ser-403 by CK1 is triggered by previous phosphorylation at Ser-397 by LATS proteins and leads to YAP1 ubiquitination by SCF(beta-TRCP) E3 ubiquitin ligase and subsequent degradation. Phosphorylated at Thr-119, Ser-138, Thr-154, Ser-367 and Thr-412 by MAPK8/JNK1 and MAPK9/JNK2, which is required for the regukation of apoptosis by YAP1. Ref.11 Ref.14 Ref.15 Ref.19 Ref.20Ubiquitinated by SCF(beta-TRCP) E3 ubiquitin ligase. Ref.20
Sequence similarities: Belongs to the YORKIE family.Contains 2 WW domains.
Research Articles on YAP1
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-YAP1 antibody
Pathways associated with anti-YAP1 antibody
Diseases associated with anti-YAP1 antibody
Disease Name |
Pubmed Publications |
Neoplasms Antibodies |
>74 publications with YAP1 and Neoplasms |
Cell Transformation, Neoplastic Antibodies |
>13 publications with YAP1 and Cell Transformation, Neoplastic |
Carcinoma, Hepatocellular Antibodies |
>13 publications with YAP1 and Carcinoma, Hepatocellular |
Liver Neoplasms Antibodies |
>12 publications with YAP1 and Liver Neoplasms |
Liver Diseases Antibodies |
>11 publications with YAP1 and Liver Diseases |
Breast Neoplasms Antibodies |
>11 publications with YAP1 and Breast Neoplasms |
Nervous System Diseases Antibodies |
>10 publications with YAP1 and Nervous System Diseases |
Neoplasms, Experimental Antibodies |
>10 publications with YAP1 and Neoplasms, Experimental |
Disease Models, Animal Antibodies |
>9 publications with YAP1 and Disease Models, Animal |
Carcinoma, Squamous Cell Antibodies |
>9 publications with YAP1 and Carcinoma, Squamous Cell |
Organs/Tissues associated with anti-YAP1 antibody
|